Medpace Holdings Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.99 (market cap $2.03B). The key difference: Medpace Holdings Inc is far larger — about 8.3× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| MEDP | TMF | |
|---|---|---|
Market Cap | $16.82B | $2.03B |
Volume | 223,093 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $630.19 | $44.14 |
52-Week Low | $393.42 | $25.19 |
Typical Hold Time | 14 Days | 28 Days |
Enterprise Value | $16.44B | — |
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) trades at $25.92, up 2.73% with increased volume of 5.2 million shares. Technical indicators show a bearish trend with strong selling pressure in moving averages, while oscillators remain neutral. The ETF saw heightened trading activity amid market focus on long-term Treasury movements.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risks. Current market conditions suggest cautious positioning given the bearish technical signals and interest rate sensitivity. The absence of fundamental metrics typical of operating companies limits traditional valuation analysis.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →